Clinical outcomes of anti‐reflux mucosal ablation for gastroesophageal reflux disease: An international bi‐institutional study

Background and Aim Anti‐reflux mucosal ablation (ARMA) is an emerging endoscopic treatment aimed at enhancing the gastroesophageal junction flap valve. This study aimed to evaluate its feasibility, effectiveness, and safety. Methods Between May 2018 and December 2022, patients with gastroesophageal...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology and hepatology 2024-01, Vol.39 (1), p.149-156
Main Authors: Shimamura, Yuto, Inoue, Haruhiro, Tanabe, Mayo, Ushikubo, Kei, Yamamoto, Kazuki, Kimoto, Yoshiaki, Nishikawa, Yohei, Ando, Ryohei, Sumi, Kazuya, Navarro, Marc Julius, Teruel Sanchez‐Vegazo, Carlos, Peñas, Beatriz, Parejo, Sofía, Martínez Sánchez, Alba, Vazquez‐Sequeiros, Enrique, Onimaru, Manabu, Albillos, Agustín, Rodriguez de Santiago, Enrique
Format: Article
Language:English
Subjects:
Ablation
Balloon treatment
Endoscopy
Endoscopy, Gastrointestinal
Endoscopy: upper GI
Esophagitis
Esophagus
Gastroesophageal reflux
Gastroesophageal Reflux - complications
Gastroesophageal reflux disease (GERD)
Humans
Hypersensitivity
Mucosa
Multivariate analysis
Patients
Quality of Life
Questionnaires
Reproducibility of Results
Retrospective Studies
Stenosis
Success
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aim Anti‐reflux mucosal ablation (ARMA) is an emerging endoscopic treatment aimed at enhancing the gastroesophageal junction flap valve. This study aimed to evaluate its feasibility, effectiveness, and safety. Methods Between May 2018 and December 2022, patients with gastroesophageal reflux disease (GERD) symptoms refractory to acid suppression medications or those dependent on such medications were enrolled for ARMA. This retrospective analysis utilized prospectively collected data from an international bi‐center study. GERD questionnaire, upper endoscopy, and 24‐h pH monitoring were conducted at 2–6 months and 12 months post‐ARMA. Clinical success was defined as a > 50% reduction in a validated GERD questionnaire. Results A total of 68 patients underwent ARMA. Definitive GERD was diagnosed in 44 (64.7%) patients, while 24 (35.3%) exhibited reflux hypersensitivity. Clinical success rates at 2–6 months and 1 year post‐ARMA were 60% (39/65) and 70% (21/30), respectively. The median GERD‐health‐related quality of life score significantly improved from 26 to 11 at 2–6 months (P 
ISSN:0815-9319
1440-1746
DOI:10.1111/jgh.16370